HomeMarket NewsMicro Cap StocksCybin's Deuterated Psychedelics Programs Receive Three New International Patents

Cybin’s Deuterated Psychedelics Programs Receive Three New International Patents

Actionable Trade Ideas

always free

lawyer psychedelic cannabis flametric aiyoshi597 gisele yashar bacsica and freedomz on shutterstock

Cybin, a clinical-stage psychedelics biopharma company, has recently been granted two patents by the United States Patent and Trademark Office (USPTO) and one by the European Patent Office (EP) for its deuterated psychedelics programs.

Based in Canada with operations in the U.S., the U.K., the Netherlands, and Ireland, Cybin is focused on developing a centralized portfolio of mental health therapies centered around DMT. The company recently acquired Small Pharma, a psychedelics biotech firm, to further strengthen its presence in the space.

Cybin’s main goal is to revolutionize mental healthcare through the development of novel deuterated psychedelic-based therapies. The company’s programs include CYB003, a deuterated psilocybin analog targeting Major Depressive Disorder (MDD), and CYB004, a deuterated DMT molecule for Generalized Anxiety Disorder (GAD). Cybin is also actively advancing its preclinical research pipeline.

Extensions of Protections

The two U.S. patents provide protection for the composition of certain deuterated DMT analogs and their medical use, as well as their novel and scalable synthesis. These patents are valid until June 2040 and March 2041, respectively. The European patent provides protection for the composition and medical use of deuterated tryptamine compounds, including deuterated psilocybin analogs and deuterated DMT analogs, until November 2041.

With these new patents, Cybin’s development programs are now protected by a total of 33 granted patents and over 170 pending applications, making it one of the leaders in the psychedelic drug development sector, according to CEO Doug Drysdale.

Cybin’s strong intellectual property position enables the company to potentially become a leader in developing novel tryptamine-based therapeutics in this key market.

Status of the Pipeline

Cybin’s novel deuterated DMT compounds, CYB004 and SPL028, are currently in Phase 1 clinical trials. These compounds aim to provide an extended DMT-like psychedelic experience while maintaining a short-duration drug profile. Preliminary study findings have shown that intravenous administration of these compounds elicits a psychedelic experience of less than 1 hour and is well-tolerated. The topline data readouts for these trials are expected in the last quarter of 2023.

Meanwhile, the deuterated psilocybin analog CYB003 has completed dosing in a Phase 2 clinical trial for Major Depressive Disorder (MDD). Interim findings have shown that the molecule leads to a robust psychedelic response at low doses while maintaining a safe and well-tolerated therapeutic profile. The topline data readout for this trial is also expected in the last quarter of 2023.

Overall, Cybin’s deuterated psychedelics programs are making significant advancements in the field of mental health therapeutics, and their innovative approach has the potential to bring about transformative changes in the treatment of various psychiatric disorders.

Photo: Benzinga edit with photo by Flametric, aiyoshi597, Gisele Yashar, Bacsica, and Freedomz on Shutterstock.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.